Analyzing Coeptis Therapeutics (COEP) and Its Competitors

Coeptis Therapeutics (NASDAQ:COEP) is one of 291 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Coeptis Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, risk, profitability, earnings and valuation.

Profitability

This table compares Coeptis Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Coeptis Therapeutics Competitors	-4,499.00%	-224.48%	-45.27%

Earnings and Valuation

This table compares Coeptis Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	-$21.27 million	-0.41
Coeptis Therapeutics Competitors	$543.33 million	-$37.31 million	6.04

Coeptis Therapeutics’ rivals have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Coeptis Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	1	0	3.00
Coeptis Therapeutics Competitors	1426	4559	11938	206	2.60

Coeptis Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 795.52%. As a group, “Biological products, except diagnostic” companies have a potential upside of 126.11%. Given Coeptis Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Coeptis Therapeutics is more favorable than its rivals.

Risk & Volatility

Coeptis Therapeutics has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ rivals have a beta of 1.04, suggesting that their average stock price is 4% more volatile than the S&P 500.

Institutional & Insider Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.